Form 4: Chromocell Therapeutics Director Richard Malamut Acquires Additional Shares
SEC Form 4 Filing
Director Richard Malamut reports purchasing 10,400 shares of Chromocell Therapeutics at an average price of $0.9447.
Summary
- Richard Malamut, a director of Chromocell Therapeutics Corp, reported acquiring 10,400 shares of common stock on September 12, 2024.
- The shares were purchased at a weighted average price of $0.9447, with individual prices ranging from $0.9206 to $0.9554 per share.
- Following the transaction, Malamut beneficially owns 91,565 shares indirectly through joint ownership with a spouse.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares can be seen as a vote of confidence, but the scale of the purchase is relatively small.
Positives
- A director's purchase of company stock can be seen as a positive signal.
Industry Context
Insider buying is often monitored as an indicator of management's confidence in the company's future prospects. It's a common practice for directors and officers to buy or sell shares of their own company, and these transactions are subject to regulatory oversight to prevent insider trading.
Key Dates
| Date | Description |
|---|---|
| August 1, 2023 | Date of Power of Attorney granted to Francis Knuettel II from Richard Malamut |
| 09/12/2024 | Date of stock transaction |
| 09/16/2024 | Date of Form 4 filing |
Keywords
Chromocell Therapeutics, Richard Malamut, stock acquisition, Form 4, insider trading, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.